Noninferiority Margin for Clinical Trials of Antibacterial Drugs for Nosocomial Pneumonia
Noninferiority (NI) clinical trials have been used to assess antibacterial drug efficacy in treating nosocomial and ventilator-associated pneumonia. Previously published trials have employed prespecified NI margins of 15% or 20% based on clinical response or microbiological endpoints. However, as those studies do not describe the statistical and clinical considerations underpinning the margins selected, their scientific plausibility cannot be substantiated. In this report, a fixed NI margin of 7% with respect to all-cause mortality is determined based on the 29% cross-study difference between the two-sided 95%, confidence intervals (CI) for the placebo estimate of 62% (95% CI: 52%, 71%) and the active control estimate of 20% (95% CI: 18%, 23%) obtained from meta-analyses of various published clinical studies. After applying discounting, we estimated the active control treatment benefit to be 14%. Due to clinical concerns, 50% of the active control treatment benefit was preserved, yielding a 7% NI margin.
Key WordsNoninferiority margin All-cause mortality Nosocomial pneumonia
Unable to display preview. Download preview PDF.
- 15.US Food and Drug Administration, Points to consider; clinical development and labeling of anti-infective drug products. 1992. Retrieved on November 4. 2009, from: https://doi.org/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070975.pdf.
- 16.US Food and Drug Administration. Guidance for industry—nosocomial pneumonia—developing antimicrobial drugs for treatment. 1998. Retrieved on January 6, 2010, from: https://doi.org/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071170.pdf.
- 17.International Conference on Harmonization. ICH E10. Choice of control group and related issues in clinical triais. Retrieved on October 26, 2009, from: https://doi.org/www.fda.gov/RegulatoryInformation/Guidances/ucm125802.htm.
- 18.US Food and Drug Administration. Guidance for industry—antimicrobial drug products: use of noninferiority studies to support approval (draft guidance). 2007 Retrieved on October 26, 2009, from: https://doi.org/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070951.pdf.
- 29.Smith IM, Champion MC, Hazard EC, Lowry L, Leaverton PE. Single and combined antibiotics in the treatment of Pseudomonas aeruginosa infections, In: Progress in Antimicrobial and Anticancer Chemotherapy: Proceedings of the 6th International Congress of Chemotherapy. Vol. 1, Baltimore. MD: University Park Press, 1970:718–724.Google Scholar
- 30.Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG, and the Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized. double-blind, multicenter study. Clin Infect Dis. 2001;32:402–412.CrossRefGoogle Scholar
- 31.Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, and the Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind. multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980–992.CrossRefGoogle Scholar
- 33.Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al. Efficacy and tolerabilily of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective, randomized, mullicenter trial. Intensive Care Med. 2001;27:493–502.CrossRefGoogle Scholar